Interestingly, we also observed lower levels of activated CD8+ TILs in the IFN-γ-treated mice compared to IFN-α2 mice (Fig 5C), whereas treatment efficacy remained identical in these groups (Fig 1A), suggesting that enhanced tumor cell recognition can compensate for the scarcity of functional T-cells. The gene discussed is IFNA2; the disease is neoplasm.